Literature DB >> 11742498

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer.

F McPhillips1, P Mullen, B P Monia, A A Ritchie, F A Dorr, J F Smyth, S P Langdon.   

Abstract

c-Raf is an essential component of the extracellular related kinase (ERK) signal transduction pathway. Immunohistochemical staining indicated that c-Raf was present in 49/53 ovarian adenocarcinomas investigated and high c-Raf expression correlated significantly with poor survival (P = 0.002). c-Raf protein was detected in 15 ovarian cancer cell lines. Antisense oligodeoxynucleotides (ODNs) (ISIS 5132 and ISIS 13650) reduced c-Raf protein levels and inhibited cell proliferation in vitro. Selectivity was demonstrated by the lack of effect of ISIS 5132 on A-Raf or ERK, while a random ODN produced only minor effects on growth and did not influence c-Raf expression. ISIS 5132 produced enhanced apoptosis and cells accumulated in S and G(2)/M phases of the cell cycle. In vivo, ISIS 5132 inhibited growth of the s.c. SKOV-3 xenograft while a mismatch ODN had no effect. These data indicate that high levels of c-Raf expression may be important in ovarian cancer and use of antisense ODNs targeted to c-Raf could provide a strategy for the treatment of this disease. (c) 2001 Cancer Research Campaign

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11742498      PMCID: PMC2363986          DOI: 10.1054/bjoc.2001.2139

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer.

Authors:  J Nemunaitis; J T Holmlund; M Kraynak; D Richards; J Bruce; N Ognoskie; T J Kwoh; R Geary; A Dorr; D Von Hoff; S G Eckhardt
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

2.  c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).

Authors:  P J O'Dwyer; J P Stevenson; M Gallagher; A Cassella; I Vasilevskaya; B P Monia; J Holmlund; F A Dorr; K S Yao
Journal:  Clin Cancer Res       Date:  1999-12       Impact factor: 12.531

Review 3.  Antisense oligonucleotide inhibition of serine/threonine kinases: an innovative approach to cancer treatment.

Authors:  Y S Cho-Chung
Journal:  Pharmacol Ther       Date:  1999 May-Jun       Impact factor: 12.310

Review 4.  raf oncogenes in carcinogenesis.

Authors:  S M Storm; U Brennscheidt; G Sithanandam; U R Rapp
Journal:  Crit Rev Oncog       Date:  1990

5.  Properties of MEKs, the kinases that phosphorylate and activate the extracellular signal-regulated kinases.

Authors:  C F Zheng; K L Guan
Journal:  J Biol Chem       Date:  1993-11-15       Impact factor: 5.157

6.  Characterization and properties of nine human ovarian adenocarcinoma cell lines.

Authors:  S P Langdon; S S Lawrie; F G Hay; M M Hawkes; A McDonald; I P Hayward; D J Schol; J Hilgers; R C Leonard; J F Smyth
Journal:  Cancer Res       Date:  1988-11-01       Impact factor: 12.701

7.  The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1.

Authors:  M Rozakis-Adcock; R Fernley; J Wade; T Pawson; D Bowtell
Journal:  Nature       Date:  1993-05-06       Impact factor: 49.962

8.  p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.

Authors:  M G Teneriello; M Ebina; R I Linnoila; M Henry; J D Nash; R C Park; M J Birrer
Journal:  Cancer Res       Date:  1993-07-01       Impact factor: 12.701

9.  Expression of epidermal growth factor receptor in normal ovary and in ovarian tumors.

Authors:  C J Stewart; O J Owens; J A Richmond; A M McNicol
Journal:  Int J Gynecol Pathol       Date:  1992-10       Impact factor: 2.762

10.  DNA analysis of breast tumour fine needle aspirates using flow cytometry.

Authors:  P A Levack; P Mullen; T J Anderson; W R Miller; A P Forrest
Journal:  Br J Cancer       Date:  1987-11       Impact factor: 7.640

View more
  12 in total

1.  Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.

Authors:  Yafei Li; Zhifu Sun; Julie M Cunningham; Marie C Aubry; Jason A Wampfler; Gary A Croghan; Cassandra Johnson; Danli Wu; Jeremiah A Aakre; Julian Molina; Liewei Wang; V Shane Pankratz; Ping Yang
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  Inhibitory effects of antisense RNA of HAb18G/CD147 on invasion of hepatocellular carcinoma cells in vitro.

Authors:  Yu Li; Peng Shang; Ai-Rong Qian; Li Wang; Yong Yang; Zhi-Nan Chen
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

3.  Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.

Authors:  Daniela Matei; Michael W Sill; Heather A Lankes; Koen DeGeest; Robert E Bristow; David Mutch; S Diane Yamada; David Cohn; Valerie Calvert; John Farley; Emanuel F Petricoin; Michael J Birrer
Journal:  J Clin Oncol       Date:  2010-11-22       Impact factor: 44.544

4.  Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.

Authors:  Anita Schwandt; Vivian E von Gruenigen; Robert M Wenham; Heidi Frasure; Susan Eaton; Nancy Fusco; Pingfu Fu; John J Wright; Afshin Dowlati; Steven Waggoner
Journal:  Invest New Drugs       Date:  2014-03-12       Impact factor: 3.850

5.  Expression of insulin-like growth factor I receptor as a biomarker for predicting prognosis in biliary tract cancer patients.

Authors:  Hideo Suzuki; Juan C Roa; Toru Kawamoto; Kazunori Ishige; Ignacio I Wistuba; Donghui Li; Melanie B Thomas; Junichi Shoda
Journal:  Mol Clin Oncol       Date:  2015-02-25

6.  Relevant molecular markers and targets.

Authors:  Kathleen M Darcy; Russel J Schilder
Journal:  Gynecol Oncol       Date:  2006-10-10       Impact factor: 5.482

7.  MEK-1 activates C-Raf through a Ras-independent mechanism.

Authors:  Deborah T Leicht; Vitaly Balan; Jun Zhu; Alexander Kaplun; Agnieszka Bronisz; Ajay Rana; Guri Tzivion
Journal:  Biochim Biophys Acta       Date:  2013-01-27

Review 8.  Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways.

Authors:  Qiang Shen; Powel H Brown
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

9.  Ovarian cancer: opportunity for targeted therapy.

Authors:  Tomoko Tagawa; Robert Morgan; Yun Yen; Joanne Mortimer
Journal:  J Oncol       Date:  2011-12-22       Impact factor: 4.375

10.  C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.

Authors:  Lucia B Jilaveanu; Christopher R Zito; Saadia A Aziz; Patricia J Conrad; John C Schmitz; Mario Sznol; Robert L Camp; David L Rimm; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 13.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.